https://www.selleckchem.com/pr....oducts/cdk2-inhibito
86%) and bronchodilator response (BDR) in FEV was diminished (10.7% vs. 6.4%) at posttreatment compared with baseline. However, the montelukast group had no significant changes in pre-FEV /FVC (p = .865) and BDR in FEV (p = .461). In addition, compared with the montelukast group, the placebo group showed no significant changes in Rrs5 (total airway resistance), Rrs5-20 (peripheral airway resistance), FeNO, and symptoms by the C-ACT. In children with well-controlled mild persistent asthma, changes in spirometry, IOS, FeNO, and
Respect!
Kommentar
Delen
